Stock CERS CERUS CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

All News Cerus Corporation

Equities

CERS

US1570851014

Real-time Estimate Cboe BZX
Other stock markets
 10:03:11 2024-05-14 am EDT 		5-day change 1st Jan Change
2.195 USD +9.75% Intraday chart for Cerus Corporation +14.86% -1.62%
May. 02 Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024
May. 02 Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Cerus Corporation, Q1 2024 Earnings Call, May 02, 2024
Cerus: Q1 Earnings Snapshot
AQ
Earnings Flash (CERS) CERUS CORPORATION Posts Q1 Revenue $43.4M, vs. Street Est of $38.4M
MT
Cerus Corporation Announces First Quarter 2024 Financial Results
BU
Cerus Corporation Reiterates Earnings Guidance for the Year Ending December 31, 2024
CI
Cerus Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
The Nomination Committee's proposed Board composition
AQ
Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024
BU
Craig-Hallum Starts Cerus With Buy Rating, $5 Price Target
MT
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets, Doubling Previous Shelf Life
AQ
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
BU
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life
CI
Cerus Says Intercept Blood System Meets Non-Inferiority Goal in Phase 3 Study; Shares Rise
MT
Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial
DJ
Transcript : Cerus Corporation - Special Call
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
BU
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
CI
Cerus Insider Sold Shares Worth $256,377, According to a Recent SEC Filing
MT
Transcript : Cerus Corporation, Q4 2023 Earnings Call, Mar 05, 2024
Cerus: Q4 Earnings Snapshot
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CERS Stock
  4. News Cerus Corporation
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW